Search results for "PPRE"

showing 10 items of 2084 documents

Characteristics, Trends, and Outcomes of Liver Transplantation for Primary Sclerosing Cholangitis in Female Versus Male Patients

2021

Background. The influence of sex on primary sclerosing cholangitis (PSC), pre- and postliver transplantation (LT) is unclear. Aims are to assess whether there have been changes in incidence, profile, and outcome in LT-PSC patients in Europe with specific emphasis on sex. Methods. Analysis of the European Liver Transplant Registry database (PSC patients registered before 2018), including baseline demographics, donor, biochemical, and clinical data at LT, immunosuppression, and outcome. Results. European Liver Transplant Registry analysis (n = 6463, 32% female individuals) demonstrated an increasing number by cohort (1980-1989, n = 159; 1990-1999, n = 1282; 2000-2009, n = 2316; 2010-2017, n =…

AdultMalemedicine.medical_specialtyTime FactorsDatabases Factualmedicine.medical_treatmentCholangitis SclerosingPopulation030230 surgeryLiver transplantationRisk AssessmentPrimary sclerosing cholangitis03 medical and health sciencesSex Factors0302 clinical medicineRisk FactorsInternal medicinemedicineHumansRegistriesHealthcare DisparitieseducationTransplantationeducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Graft SurvivalImmunosuppressionHealth Status DisparitiesMiddle Agedmedicine.diseaseLiver TransplantationEuropeTransplantationTreatment OutcomeMale patientCohortFemale030211 gastroenterology & hepatologybusinessTransplantation
researchProduct

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell glo…

2011

Abstract Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the contr…

AdultMalemedicine.medical_specialtyTime FactorsTransplantation ConditioningAdolescentmedicine.medical_treatmentImmunologyMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationBiochemistryGastroenterologyDisease-Free Survivallaw.inventionRandomized controlled triallawRecurrenceInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceSurvival rateAntilymphocyte SerumImmunosuppression Therapybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationSurvival RateGraft-versus-host diseaseMethotrexateHematologic NeoplasmsChronic DiseaseCyclosporineFemalebusinessImmunosuppressive AgentsBlood
researchProduct

Remission of severe rheumatoid arthritis following liver transplantation.

1993

We present the case of a 32-year-old male who suffered from severe RA from the age of 21 years. After 9 years of active disease and poor response to therapy the patient developed severe hepatitis induced by the NSAID pirprofen. He went into fulminant hepatic failure necessitating emergency liver transplantation. Liver transplantation was followed by clinical and laboratory remission of his RA and he has remained virtually asymptomatic for more than 3.5 years. The possibility that this favourable clinical course was due to the immunosuppressive effect of the liver transplant rather than the ensuing immunosuppressive therapy is discussed.

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentRemission SpontaneousArthritisLiver transplantationAsymptomaticGastroenterologyArthritis RheumatoidFulminant hepatic failureRheumatologyPirprofenInternal medicinemedicineHumansPharmacology (medical)HepatitisPhenylpropionatesbusiness.industrymedicine.diseaseSurgeryLiver TransplantationTransplantationRheumatoid arthritismedicine.symptomChemical and Drug Induced Liver InjurybusinessImmunosuppressive Agentsmedicine.drugFollow-Up StudiesBritish journal of rheumatology
researchProduct

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated don…

2009

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Anti-T-cell globulins (ATGs) might lower the incidence of GVHD. We did a prospective, randomised, multicentre, open-label, phase 3 trial to compare standard GVHD prophylaxis with ciclosporin and methotrexate with or without anti-Jurkat ATG-Fresenius (ATG-F).Between May 26, 2003, and Feb 8, 2007, 202 patients with haematological malignancies were centrally randomly assigned using computer-generated centre-stratified block randomisation between treatment groups receiving ciclosporin and methotrexate with or without additional ATG-F. One patie…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentT-LymphocytesGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterologyInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceProspective StudiesAntilymphocyte Serumbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationMiddle AgedCiclosporinmedicine.diseaseSurvival AnalysisAnti-thymocyte globulinSurgeryTransplantationGraft-versus-host diseaseMethotrexateOncologyHematologic NeoplasmsCyclosporineRegression AnalysisDrug Therapy CombinationFemaleTransplantation ConditioningbusinessImmunosuppressive Agentsmedicine.drugThe Lancet. Oncology
researchProduct

Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation i…

2017

Eighty-one patients with high-risk hematological malignancies received unmanipulated haploidentical stem cell transplants (haploSCT) using the same protocol at four Spanish institutions. The conditioning regimen was thiotepa, busulfan and fludarabine; following bone marrow or peripheral blood infusion. GvHD prophylaxis with high-dose cyclophosphamide on days +3 and +4, and IV tacrolimus from day +5 was administered. 62% were in complete remission, 17% had received previous allogeneic SCT and 44% had a high-very high refined disease risk index. One patient had primary graft failure and three more died before +21. The median days to neutrophil and platelet recoveries were +18 and +23, respect…

AdultMalemedicine.medical_specialtyTransplantation ConditioningCyclophosphamideAdolescentGraft vs Host DiseaseThioTEPAGastroenterologyTacrolimus03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineHumansCyclophosphamideAgedRetrospective StudiesTransplantationbusiness.industryHematologyMiddle Agedmedicine.diseaseTacrolimusFludarabineSurgeryTransplantationsurgical procedures operativemedicine.anatomical_structureGraft-versus-host disease030220 oncology & carcinogenesisHematologic NeoplasmsTransplantation HaploidenticalFemaleBone marrowbusinessBusulfanImmunosuppressive Agents030215 immunologymedicine.drugBone marrow transplantation
researchProduct

Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant

2009

We assessed the efficacy and outcome of low through level of calcineurin inhibitors (CNI) and introducing mycophenolate mofetil (MMF) in liver transplant (LT) patients with CNI-related renal dysfunction. Thirty LT patients were converted to combined therapy and compared with 30 patients used as a contemporary control group receiving CNI only. The two groups were matched for sex, age, months after LT, immunosuppressive treatment, creatinine level, presence of diabetes and calculated glomerular filtration rate (GFR) via Cockroft-Gault method. After two years, in the MMF serum creatinine decreased from 1.65 mg/dL (range 1.33-3.5) to 1.4 mg/dL (range 0.9-4.7) (p = 0.002) and GFR increased from …

AdultMalemedicine.medical_specialtyUrinary systemmedicine.medical_treatmentCalcineurin InhibitorsUrologyRENAL DYSFUNCTIONRenal functionCALCINEURIN INHIBITORS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MYCOPHENOLATE MOFETIL; RENAL DYSFUNCTIONLiver transplantationKidney Function TestsTacrolimusMycophenolic acidNephrotoxicitychemistry.chemical_compoundmedicineHumansMYCOPHENOLATE MOFETILAgedTransplantationCreatinineIMMUNOSUPPRESSIONDose-Response Relationship Drugbusiness.industryGraft SurvivalMiddle AgedMycophenolic AcidTacrolimusLiver TransplantationCalcineurinliver transplantTreatment OutcomechemistryCreatinineImmunologyKidney Failure ChronicDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsGlomerular Filtration Ratemedicine.drug
researchProduct

Allogenic simple limbal epithelial transplantation (alloSLET) from cadaveric donor eyes in patients with persistent corneal epithelial defects

2020

Background/aimTo describe the clinical outcome of allogenic simple limbal epithelial transplantation (alloSLET) utilising tissue from cadaveric donor eyes after failed re-epithelialisation of the corneal surface.MethodsMedical records of 14 eyes from 14 patients treated for persistent corneal epithelial defects with alloSLET were reviewed. The primary outcome measure was complete epithelialisation of the corneal surface. Secondary outcome measures were best corrected visual acuity (BCVA) and postoperative side effects due to surgery or medical therapy.ResultsOf the 14 eyes, 7 received alloSLET only and 7 alloSLET together with penetrating keratoplasty (PK). Thirteen (92.9%) of 14 eyes had a…

AdultMalemedicine.medical_specialtygenetic structuresPrednisoloneVisual AcuityLimbus CorneaeCorneal DiseasesCellular and Molecular NeuroscienceRe-EpithelializationCorneaOphthalmologyCadaverHumansMedicineEffective treatmentIn patientAgedRetrospective StudiesCorneal epitheliumAged 80 and overbusiness.industryEpithelium CornealCadaveric donorMiddle AgedMycophenolic AcidAllograftsTissue Donorseye diseasesSensory SystemsTransplantationOphthalmologyTreatment Outcomemedicine.anatomical_structureFemalesense organsbusinessBandage contact lensOcular surfaceImmunosuppressive AgentsBritish Journal of Ophthalmology
researchProduct

Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational stu…

2011

Introduction: About 30-40% of patients with acute severe ulcerative colitis (UC) fail to respond to intensive intravenous (iv) corticosteroid treatment. Iv cyclosporine and infliximab are an effective rescue therapy in steroid-refractory UC patients but up to now it is still unclear which is the best therapeutic choice. Methods: We reviewed our series of severe steroid-refractory colitis admitted consecutively since 1994 comparing two historical cohort treated with iv cyclosporine (2 mg/kg) or iv infliximab (5 mg/kg). The main outcome was the colectomy rate at 3 months, 12 months and at the end of the follow-up. Results: A total of 65 patients were included: 35 in the cyclosporine group and…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAnti-Inflammatory AgentsAzathioprineKaplan-Meier EstimateGastroenterologyCohort StudiesRefractoryInternal medicinemedicineHumansColitisColectomyRetrospective StudiesColectomybiologybusiness.industryC-reactive proteinGastroenterologyAntibodies MonoclonalRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyUlcerative colitisInfliximabInfliximabSurgeryLogistic ModelsTreatment OutcomeCyclosporinebiology.proteinColitis UlcerativeFemalebusinessImmunosuppressive AgentsFollow-Up Studiesmedicine.drugJournal of Crohn's and Colitis
researchProduct

Immunosuppressive treatment of rippling muscles in patients with myasthenia gravis

2000

Rippling muscle disease is a rare autosomal dominant disorder that may occur sporadically. In this report two patients presenting with rippling muscles followed by myasthenia gravis are described. Our first patient developed rippling muscles about 1 month after infection with Yersinia enterocolitica. Two years later myasthenia gravis appeared. Our second patient had a 2-year history of asthma prior to the onset of rippling muscles which preceded the myasthenic symptoms by 4-8 weeks. Acetylcholine receptor and anti-skeletal muscle antibody titers were positive in both patients. In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosu…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAzathioprineGastroenterologyMuscular DiseasesPhysical StimulationInternal medicineAzathioprineMyasthenia GravismedicineHumansGenetics (clinical)AsthmaAcetylcholine receptorbusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseMyasthenia gravisNeurologyPyridostigmineRipplingPediatrics Perinatology and Child HealthImmunologyNeurology (clinical)medicine.symptombusinessImmunosuppressive AgentsMuscle ContractionPyridostigmine BromideMuscle contractionmedicine.drugNeuromuscular Disorders
researchProduct

Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immuno…

2012

Abstract Background Predictors of sustained virological response (SVR) to antiviral therapy post-liver transplantation (LT) for chronic hepatitis C are needed. In non-transplanted patients, viral kinetics can predict SVR. Objectives To determine the early viral kinetics in LT recipients with different immunosuppression (tacrolimus – Tac- vs. cyclosporine – CsA-) during treatment with peg-IFN + RBV. Study design Prospective pilot study in HCV-1b infected patients: (LT CsA n = 8; Tac n = 8; non-LT n = 4), treated with IFN α-2a vs. α-2b (180 μg or 1.5 μg/kg, respectively) once weekly plus weight-based RBV. Median CsA or Tac baseline trough levels were 141 and 7.70 ng/mL, respectively. HCV-RNA …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPilot ProjectsHepacivirusInterferon alpha-2Biologymedicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene GlycolsImmunocompromised Hostchemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesAgedRibavirinInterferon-alphaImmunosuppressionHepatitis C ChronicMiddle AgedViral LoadViral kineticsRecombinant ProteinsTacrolimusLiver TransplantationTransplantationKineticsTreatment OutcomeInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyFemaleViral loadmedicine.drugJournal of Clinical Virology
researchProduct